查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387358

抗忧郁症市场报告：2030 年趋势、预测与竞争分析

Antidepressant Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

抗忧郁症趋势和预测

预计到 2030 年，全球抗忧郁症市场将达到约 218 亿美元，2024 年至 2030 年复合年增长率为 5.3%。这个市场的主要驱动因素是全球忧郁症、强迫性精神官能症和其他情绪障碍盛行率的上升，以及人们对心理健康意识的增强。全球抗忧郁症市场前景看好，重度忧郁症、强迫性精神官能症、整体焦虑症、恐慌症市场蕴藏着商机。

抗忧郁症市场洞察

Lucintel 预测，由于重度忧郁症和焦虑症的增加，选择性血清素再回收抑制剂在预测期内仍将是最大的细分市场。

在这个市场中，重度忧郁症重度忧郁症仍然是最大的部分，因为它的盛行率很高，而且年轻人对忧郁症治疗和管理的认识不断提高。

由于忧郁症患者数量不断增加、老年人口迅速增长以及该地区主要企业的存在，北美在预测期内可能仍然是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 未来哪个细分市场成长较快？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球抗忧郁症市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球抗忧郁症市场趋势（2018-2023）与预测（2024-2030）
  • 全球抗忧郁症市场（按产品）
    • 三环抗忧郁药物
    • 选择性血清素再回收抑制剂
    • 血清素去甲肾上腺素再回收抑制剂
    • 单胺氧化酶抑制剂
    • 血清素拮抗剂/再回收抑制剂
    • 其他的
  • 按忧郁症分類的全球抗忧郁症市场
    • 重度忧郁症
    • 强迫性精神官能症
    • 整体焦虑症
    • 恐慌症
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球抗忧郁症市场区域分布
  • 北美抗忧郁症市场
  • 欧洲抗忧郁症市场
  • 亚太地区抗忧郁症市场
  • 其他地区抗忧郁症市场

第五章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球抗忧郁症市场成长机会（按产品）
    • 忧郁症带来的全球抗忧郁症市场成长机会
    • 全球抗忧郁症市场成长机会（按地区）
  • 全球抗忧郁症市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球抗忧郁症市场的产能
    • 全球抗忧郁症市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck
简介目录

Antidepressant Trends and Forecast

The future of the global antidepressant market looks promising with opportunities in the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder markets. The global antidepressant market is expected to reach an estimated $21.8 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are rising prevalence of depression, obsessive-compulsive disorder, and other mood disorders across the globe and growing awareness about mental health.

A more than 150-page report is developed to help in your business decisions.

Antidepressant by Segment

The study includes a forecast for the global antidepressant by product, depressive disorder, and region.

Antidepressant Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist & Reuptake Inhibitors
  • Others

Antidepressant Market by Depressive Disorder [Shipment Analysis by Value from 2018 to 2030]:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Antidepressant Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Antidepressant Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antidepressant companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antidepressant companies profiled in this report include-

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck

Antidepressant Market Insights

Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period due to rising occurrence of major depressive disorder and anxiety disorders.

Within this market, major depressive disorder will remain the largest segment due to high prevalence of major depressive disorder and increasing awareness towards treatment and management of depression among youth population.

North America will remain the largest region over the forecast period due to increasing cases of depression, surge in the geriatric population, and presence of major players in the region.

Features of the Global Antidepressant Market

Market Size Estimates: Antidepressant market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antidepressant market size by product, depressive disorder, and region in terms of value ($B).

Regional Analysis: Antidepressant market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, depressive disorders, and regions for the antidepressant market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antidepressant market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the antidepressant market size?

Answer: The global antidepressant market is expected to reach an estimated $21.8 billion by 2030.

Q2. What is the growth forecast for antidepressant market?

Answer: The global antidepressant market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antidepressant market?

Answer: The major drivers for this market are rising prevalence of depression, obsessive-compulsive disorder, and other mood disorders across the globe and growing awareness about mental health.

Q4. What are the major segments for antidepressant market?

Answer: The future of the antidepressant market looks promising with opportunities in the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder markets.

Q5. Who are the key antidepressant market companies?

Answer: Some of the key antidepressant companies are as follows:

  • Alkermes
  • AbbVie
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • H. Lundbeck
  • Merck

Q6. Which antidepressant market segment will be the largest in future?

Answer: Lucintel forecasts that selective serotonin reuptake inhibitor will remain the largest segment over the forecast period due to rising occurrence of major depressive disorder and anxiety disorders.

Q7. In antidepressant market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing cases of depression, surge in the geriatric population, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the antidepressant market by product (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others), depressive disorder (major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antidepressant Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Antidepressant Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Antidepressant Market by Product
    • 3.3.1: Tricyclic Antidepressants
    • 3.3.2: Selective Serotonin Reuptake Inhibitors
    • 3.3.3: Serotonin-Norepinephrine Reuptake Inhibitors
    • 3.3.4: Monoamine Oxidase Inhibitors
    • 3.3.5: Serotonin Antagonist & Reuptake Inhibitors
    • 3.3.6: Others
  • 3.4: Global Antidepressant Market by Depressive Disorder
    • 3.4.1: Major Depressive Disorder
    • 3.4.2: Obsessive-Compulsive Disorder
    • 3.4.3: Generalized Anxiety Disorder
    • 3.4.4: Panic Disorder
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Antidepressant Market by Region
  • 4.2: North American Antidepressant Market
    • 4.2.2: North American Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.3: European Antidepressant Market
    • 4.3.1: European Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.3.2: European Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.4: APAC Antidepressant Market
    • 4.4.1: APAC Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.4.2: APAC Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others
  • 4.5: ROW Antidepressant Market
    • 4.5.1: ROW Antidepressant Market by Product: Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors, and Others
    • 4.5.2: ROW Antidepressant Market by Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Antidepressant Market by Product
    • 6.1.2: Growth Opportunities for the Global Antidepressant Market by Depressive Disorder
    • 6.1.3: Growth Opportunities for the Global Antidepressant Market by Region
  • 6.2: Emerging Trends in the Global Antidepressant Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Antidepressant Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antidepressant Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Alkermes
  • 7.2: AbbVie
  • 7.3: Eli Lilly
  • 7.4: F. Hoffmann-La Roche
  • 7.5: GlaxoSmithKline
  • 7.6: H. Lundbeck
  • 7.7: Merck